InvestorsObserver
×
News Home

Analyst Rating: Will Xenetic Biosciences Inc (XBIO) Stock Outperform the Market?

Thursday, October 22, 2020 03:29 PM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Xenetic Biosciences Inc (XBIO) Stock Outperform the Market?

Wall Street is positive on Xenetic Biosciences Inc (XBIO). On average, analysts give Xenetic Biosciences Inc a Strong Buy rating. The average price target is $2.25, which means analysts expect the stock to increase by 136.84% over the next twelve months.

That average ranking earns Xenetic Biosciences Inc an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating XBIO a Strong Buy today. Find out what this means to you and get the rest of the rankings on XBIO!

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.

InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Xenetic Biosciences Inc Stock Today?

Xenetic Biosciences Inc (XBIO) stock is trading at $0.95 as of 3:26 PM on Thursday, Oct 22, a gain of $0.08, or 9.17% from the previous closing price of $0.87. The stock has traded between $0.87 and $0.99 so far today. Volume today is more active than usual. So far 586,935 shares have traded compared to average volume of 158,087 shares.

Click Here to get the full report on Xenetic Biosciences Inc (XBIO) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App